Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5825274 | Clinical Therapeutics | 2014 | 21 Pages |
Abstract
Statistical heterogeneity between studies was high, although clinically the studies represented medical practice. Without randomized clinical trials directly comparing darbepoetin alfa and short-acting ESAs, these findings are tentative and future research is warranted. This review shows that good-quality, reliable data from head-to-head trials are lacking. The best available evidence comes from prospective ESA-arm data. Mean weekly doses, dose increases, and dose decreases suggest a dose efficiency for darbepoetin alfa compared with short-acting ESAs.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Carol A. PhD, Gillian MSc, Julie MRes, Jos MD, PhD, Lucie PhD, Laurent MD, Simon MD, PhD,